FDA's plan to boost cheaper copycat drugs could stall at the patent office
The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the opposite direction.
Benzinga.com
STAT+: How the first nine drug companies won priority review vouchers from Marty Makary's FDA
WASHINGTON — Commissioner Marty Makary wants the Food and Drug Administration to move more quickly. The launch of a new priority review voucher program in June was no exception. The agency promised winners a one-to-two month review of their drug ...
FDA Commissioner Dr. Makary on lifting HRT warnings: 50M women haven't experienced the benefits
FDA Commissioner Dr. Marty Makary joins 'Squawk box' to discuss questions around the use of female hormone replacement therapy, why the FDA is lifting warnings on HRT, future of women's health, and more.
STAT
How the first nine drug companies won priority review vouchers from Marty Makary’s FDA
Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. WASHINGTON — Commissioner Marty Makary wants the Food and Drug Administration to ...
Feedback